Uppdrag | 13 Sep 2024

Setterwalls advised Ascelia Pharma in connection with a fully subscribed rights issue of units

Responsive image

Setterwalls has advised Ascelia Pharma AB, listed on Nasdaq Stockholm, in connection with a fully subscribed rights issue of units.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Through the rights issue, Ascelia Pharma receives initial issue proceeds of approximately SEK 105 million before issue costs.

  • This field is for validation purposes and should be left unchanged.

Do you want to get in touch with us?

Please fill out the form and we will contact you as soon as possible.